103 related articles for article (PubMed ID: 35970756)
1. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
Bennett R; Thompson E; Tam C
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
Ahn IE; Davids MS
Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
[TBL] [Abstract][Full Text] [Related]
3. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
Thomalla D; Beckmann L; Grimm C; Oliverio M; Meder L; Herling CD; Nieper P; Feldmann T; Merkel O; Lorsy E; da Palma Guerreiro A; von Jan J; Kisis I; Wasserburger E; Claasen J; Faitschuk-Meyer E; Altmüller J; Nürnberg P; Yang TP; Lienhard M; Herwig R; Kreuzer KA; Pallasch CP; Büttner R; Schäfer SC; Hartley J; Abken H; Peifer M; Kashkar H; Knittel G; Eichhorst B; Ullrich RT; Herling M; Reinhardt HC; Hallek M; Schweiger MR; Frenzel LP
Blood; 2022 Nov; 140(20):2113-2126. PubMed ID: 35704690
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
Chong SJF; Zhu F; Dashevsky O; Mizuno R; Lai JX; Hackett L; Ryan CE; Collins MC; Iorgulescu JB; Guièze R; Penailillo J; Carrasco R; Hwang YC; Muñoz DP; Bouhaddou M; Lim YC; Wu CJ; Allan JN; Furman RR; Goh BC; Pervaiz S; Coppé JP; Mitsiades CS; Davids MS
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37751299
[TBL] [Abstract][Full Text] [Related]
5. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract][Full Text] [Related]
6. SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies.
Forsberg M; Konopleva M
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):1-14. PubMed ID: 38007372
[TBL] [Abstract][Full Text] [Related]
7. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blombery P; Lew TE; Dengler MA; Thompson ER; Lin VS; Chen X; Nguyen T; Panigrahi A; Handunnetti SM; Carney DA; Westerman DA; Tam CS; Adams JM; Wei AH; Huang DCS; Seymour JF; Roberts AW; Anderson MA
Blood; 2022 Feb; 139(8):1198-1207. PubMed ID: 34469514
[TBL] [Abstract][Full Text] [Related]
8. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
Thijssen R; Tian L; Anderson MA; Flensburg C; Jarratt A; Garnham AL; Jabbari JS; Peng H; Lew TE; Teh CE; Gouil Q; Georgiou A; Tan T; Djajawi TM; Tam CS; Seymour JF; Blombery P; Gray DHD; Majewski IJ; Ritchie ME; Roberts AW; Huang DCS
Blood; 2022 Nov; 140(20):2127-2141. PubMed ID: 35709339
[TBL] [Abstract][Full Text] [Related]
9. Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
Khalsa JK; Cha J; Utro F; Naeem A; Murali I; Kuang Y; Vasquez K; Li L; Tyekucheva S; Fernandes SM; Veronese L; Guieze R; Sasi BK; Wang Z; Machado JH; Bai H; Alasfour M; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Paweletz CP; Leshchiner I; Parida L; Getz G; Brown JR
Blood; 2023 Aug; 142(5):421-433. PubMed ID: 37146250
[TBL] [Abstract][Full Text] [Related]
10. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.
Liu J; Li S; Wang Q; Feng Y; Xing H; Yang X; Guo Y; Guo Y; Sun H; Liu X; Yang S; Mei Z; Zhu Y; Cheng Z; Chen S; Xu M; Zhang W; Wan N; Wang J; Ma Y; Zhang S; Luan X; Xu A; Li L; Wang H; Yang X; Hong Y; Xue H; Yuan X; Hu N; Song X; Wang Z; Liu X; Wang L; Liu Y
Blood; 2024 May; 143(18):1825-1836. PubMed ID: 38211332
[TBL] [Abstract][Full Text] [Related]
11. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).
Patel VM; Balakrishnan K; Douglas M; Tibbitts T; Xu EY; Kutok JL; Ayers M; Sarkar A; Guerrieri R; Wierda WG; O'Brien S; Jain N; Stern HM; Gandhi V
Leukemia; 2017 Sep; 31(9):1872-1881. PubMed ID: 28017967
[TBL] [Abstract][Full Text] [Related]
12. The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Lampson BL; Davids MS
Curr Hematol Malig Rep; 2017 Feb; 12(1):11-19. PubMed ID: 28116634
[TBL] [Abstract][Full Text] [Related]
13. Enhancing venetoclax activity in hematological malignancies.
Satta T; Grant S
Expert Opin Investig Drugs; 2020 Jul; 29(7):697-708. PubMed ID: 32600066
[TBL] [Abstract][Full Text] [Related]
14. The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells
Fatima N; Shen Y; Crassini K; Burling O; Thurgood L; Iwanowicz EJ; Lang H; Karanewsky DS; Christopherson RI; Mulligan SP; Best OG
Leuk Lymphoma; 2024 May; 65(5):585-597. PubMed ID: 38227293
[TBL] [Abstract][Full Text] [Related]
15. Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia.
Chen Z; Cretenet G; Carnazzo V; Simon-Molas H; Kater AP; Windt GJWV; Eldering E
Haematologica; 2024 Jan; 109(1):151-162. PubMed ID: 37439352
[TBL] [Abstract][Full Text] [Related]
16. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.
Moujalled DM; Brown FC; Chua CC; Dengler MA; Pomilio G; Anstee NS; Litalien V; Thompson E; Morley T; MacRaild S; Tiong IS; Morris R; Dun K; Zordan A; Shah J; Banquet S; Halilovic E; Morris E; Herold MJ; Lessene G; Adams JM; Huang DCS; Roberts AW; Blombery P; Wei AH
Blood; 2023 Feb; 141(6):634-644. PubMed ID: 36219880
[TBL] [Abstract][Full Text] [Related]
17. The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation.
Liu P; Zhao L; Zitvogel L; Kepp O; Kroemer G
Cell Death Differ; 2023 Dec; 30(12):2447-2451. PubMed ID: 37845384
[TBL] [Abstract][Full Text] [Related]
18. Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency.
Leblay N; Ahn S; Tilmont R; Poorebrahim M; Maity R; Lee H; Barakat E; Alberge JB; Sinha S; Jaffer A; Barwick BG; Boise LH; Bahlis N; Neri P
Blood; 2024 Jan; 143(1):42-56. PubMed ID: 37729611
[TBL] [Abstract][Full Text] [Related]
19. BCL-2 inhibition in haematological malignancies: Clinical application and complications.
Fowler-Shorten DJ; Hellmich C; Markham M; Bowles KM; Rushworth SA
Blood Rev; 2024 May; 65():101195. PubMed ID: 38523032
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects.
Tariq S; Tariq S; Khan M; Azhar A; Baig M
Cureus; 2020 Jun; 12(6):e8908. PubMed ID: 32742874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
